Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.6926 +0.0454 (+7.01%)
Streaming Delayed Price Updated: 11:43 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
From Ocugen
Via GlobeNewswire
OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
With Ocugen receiving a green light to move ahead with a key retinal therapeutic, OCGN stock jumped on the positive implications. 
Via InvestorPlace
Why Ocugen Shares Are Popping Off
Ocugen shares are trading higher by 14% during Wednesday's session. The company provided an update on its business activities and financial status for 2023. 
Via Benzinga
What's Going On With Ocugen Stock?
Ocugen shares are trading lower by 6.3% during Tuesday's session. The stock is pulling back after hitting a new 52-week high Monday and following recent, key business updates. 
Via Benzinga
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc. (OCGN)
From Robbins LLP
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
From The Rosen Law Firm, P.A.
Via Business Wire
Why Is Auddia (AUUD) Stock Up 192% Today?
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Ocugen Shares Are Trading Higher
Ocugen shares are trading higher by 7.7% during Monday's session. The company announced U.S. FDA clearance of the IND amendment to initiate a Phase 3 clinical trial of OCU400. 
Via Benzinga
Exposures Product Safety
Why Is Ocugen (OCGN) Stock Up 7% Today?
Ocugen is returning to its eye treatment roots after a brief life as a Covid-19 vaccine meme stock in 2021 delivered OCGN stock no results. 
Via InvestorPlace
Exposures COVID-19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Why Ocugen Stock Is Climbing Today
Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ocugen (OCGN) Q4 2023 Earnings Call Transcript
OCGN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
OCGN Stock Falls Ocugen Must Restate Its Financials
After an impressive rally to date, investors appear to be in selling mode with OCGN stock on the news it will need to restate its financials. 
Via InvestorPlace
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
Earnings Scheduled For April 2, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.